Anastasios Athanasopoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anastasios Athanasopoulos has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
P. Perimenis
14 shared publicationsPetros Perimenis
14 shared publications- Petros Perimenis
Department of Urology, Taunton and Somerset Hospital, Taunton, Somerset, UK
14 shared publications G. Barbalias
University of Patras
12 shared publicationsK. Gyftopoulos
Department of Anatomy, University of Patras, School of Medicine, Patras, Greece
11 shared publicationsKonstantinos Giannitsas
Department of Urology, Patras University Hospital, Patras, Greece
10 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by Elsevier in Continence Reports
- Vol. 6
Acute urinary retention in a woman due to large urethral diverticulum: A case report
- 3 April 2023
- Published by Elsevier in Continence Reports
- Vol. 6
Open AccessAcute urinary retention in a woman due to large urethral diverticulum: A case report
- Open Access
- 26 September 2022
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 94 (3) , 366-368
Nocturia due to nocturnal polyuria (NP). A common disorder
To the Editor, Nocturia is a significantly underestimated medical problem that affects seriously patients' quality of life, work engagement, productivity, and overall life conditions per se. Nocturia is a common condition, proven to be the most bothersome for patients with Lower Urinary Tract Symptoms (LUTS). People with two or more events of micturition per night have a significant increase in mortality rate and an increased risk of fall-related fractures if they visit the toilet two or more times per night [...].
- 26 September 2022
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 94 (3) , 366-368
Open AccessNocturia due to nocturnal polyuria (NP). A common disorder
To the Editor, Nocturia is a significantly underestimated medical problem that affects seriously patients' quality of life, work engagement, productivity, and overall life conditions per se. Nocturia is a common condition, proven to be the most bothersome for patients with Lower Urinary Tract Symptoms (LUTS). People with two or more events of micturition per night have a significant increase in mortality rate and an increased risk of fall-related fractures if they visit the toilet two or more times per night [...].
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S25-S26
Efficacy of fesoterodine fumarate in Neurogenic Detrusor Overactivity (NDO) due to Spinal Cord Lesion (SCL) or Multiple Sclerosis (MS) – A prospective study
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S25-S26
Efficacy of fesoterodine fumarate in Neurogenic Detrusor Overactivity (NDO) due to Spinal Cord Lesion (SCL) or Multiple Sclerosis (MS) – A prospective study
- 2 April 2020
- Published by Springer Nature in International Urology and Nephrology
- Vol. 52 (8) , 1407-1420
The hemodynamic interactions of combination therapy with α-blockers and phosphodiesterase-5 inhibitors compared to monotherapy with α-blockers: a systematic review and meta-analysis
Objective The present study systematically reviewed the safety of combined treatment with an alpha blocker and phosphodiesterase-5 inhibitor. Materials and methods The study was performed according to the PRISMA statement. The included studies were randomized controlled trials that included at least one group on alpha-blocker monotherapy and one group on a combined treatment with an alpha blocker and phosphodiesterase-5 inhibitor. The primary endpoints were the hemodynamic effects of the two groups, specifically the clinically significant changes and a positive orthostatic test. The secondary endpoints were the adverse events of the two treatment modalities. Results A total of 6687 studies were screened, and 19 randomized controlled trials were eligible for the meta-analysis. The combined treatment more often produced a clinically significant hemodynamic change with an MD of 4.73 (CI 1.25, 17.94; I2 = 0%; p = 0.02), but the positive orthostatic test was similar between the groups with an MD of 1.64 (CI 0.36, 7.47; I2 = 50%; p = 0.52). The meta-analysis of adverse events favored alpha-blocker monotherapy with an OD of 0.5 (CI 0.32, 0.78; I2 = 44%; p = 0.002). However, if we consider only the adverse events due to hypotension, the result was similar between the two groups with an OD of 0.97 (CI 0.58, 1.64; I2 = 0%; p = 0.92). Conclusion The combined treatment may produce a clinically significant hemodynamic change. The combination of alpha blocker and phosphodiesterase-5 inhibitor was safe because it did not increase the rate of adverse events due to hypotension.
- 2 April 2020
- Published by Springer Nature in International Urology and Nephrology
- Vol. 52 (8) , 1407-1420
The hemodynamic interactions of combination therapy with α-blockers and phosphodiesterase-5 inhibitors compared to monotherapy with α-blockers: a systematic review and meta-analysis
Objective The present study systematically reviewed the safety of combined treatment with an alpha blocker and phosphodiesterase-5 inhibitor. Materials and methods The study was performed according to the PRISMA statement. The included studies were randomized controlled trials that included at least one group on alpha-blocker monotherapy and one group on a combined treatment with an alpha blocker and phosphodiesterase-5 inhibitor. The primary endpoints were the hemodynamic effects of the two groups, specifically the clinically significant changes and a positive orthostatic test. The secondary endpoints were the adverse events of the two treatment modalities. Results A total of 6687 studies were screened, and 19 randomized controlled trials were eligible for the meta-analysis. The combined treatment more often produced a clinically significant hemodynamic change with an MD of 4.73 (CI 1.25, 17.94; I2 = 0%; p = 0.02), but the positive orthostatic test was similar between the groups with an MD of 1.64 (CI 0.36, 7.47; I2 = 50%; p = 0.52). The meta-analysis of adverse events favored alpha-blocker monotherapy with an OD of 0.5 (CI 0.32, 0.78; I2 = 44%; p = 0.002). However, if we consider only the adverse events due to hypotension, the result was similar between the two groups with an OD of 0.97 (CI 0.58, 1.64; I2 = 0%; p = 0.92). Conclusion The combined treatment may produce a clinically significant hemodynamic change. The combination of alpha blocker and phosphodiesterase-5 inhibitor was safe because it did not increase the rate of adverse events due to hypotension.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1992
Is the combination of alpha-blocker and phosphodiesterase-5 inhibitor better in improving the lower urinary tract symptoms and erectile dysfunction in comparison to monotherapy? A systematic review and meta-analysis
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1992
Is the combination of alpha-blocker and phosphodiesterase-5 inhibitor better in improving the lower urinary tract symptoms and erectile dysfunction in comparison to monotherapy? A systematic review and meta-analysis
- 1 October 2017
- Published by Elsevier in European Urology Focus
- Vol. 3 (4-5) , 498-501
A Classification System for Urodynamic Evaluation of Lower Urinary Tract System Dysfunction
- 1 October 2017
- Published by Elsevier in European Urology Focus
- Vol. 3 (4-5) , 498-501
A Classification System for Urodynamic Evaluation of Lower Urinary Tract System Dysfunction
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 195 (4) , e1020
MP77-12 COITAL INCONTINENCE IN WOMEN WITH URINARY INCONTINENCE: RESULTS FROM AN INTERNATIONAL CROSS-SECTIONAL STUDY
Coital incontinence (CI) is an underreported symptom in sexually active women with pelvic floor dysfunction. Aims of our study were to evaluate the prevalence of CI in women with Urinary Incontinence (UI), its impact on female sexuality and quality of life (QoL) and associated risks factors.
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 195 (4) , e1020
MP77-12 COITAL INCONTINENCE IN WOMEN WITH URINARY INCONTINENCE: RESULTS FROM AN INTERNATIONAL CROSS-SECTIONAL STUDY
Coital incontinence (CI) is an underreported symptom in sexually active women with pelvic floor dysfunction. Aims of our study were to evaluate the prevalence of CI in women with Urinary Incontinence (UI), its impact on female sexuality and quality of life (QoL) and associated risks factors.
- 1 December 2015
- Published by Wolters Kluwer Health in Current Urology
- Vol. 8 (4) , 169-174
Intravesical Therapies for Radiation Cystitis
Objective: The purpose of this study was to summarize developments during the last decade in intravesical treatments for radiation cystitis. Radiation used to treat pelvic malignancies inadvertently damages the urinary bladder leading to acute as well as chronic symptoms. Late sequelae may take years to develop and include storage symptoms and hematuria, which may be life-threatening in severe cases. Conservative measures, surgical interventions, and systematically or intravesically administered agents represent treatment choices. Methods: MEDLINE and PubMed were searched to retrieve clinical data on the subject, published in peer-reviewed journals from 2002 onwards. Results: Historically referenced intravesical treatments such as aluminium salts and formalin, were not investigated in recent studies. The replenishment of the glycosaminoglycan layer of the bladder mucosa shows promise in reducing acute symptoms and possibly long-term bladder damage, but needs further investigation. Botulinum toxin also represents a new alternative treatment for radiation cystitis but its mechanism of action and efficacy should be evaluated in future trials. Conclusion: There is a paucity of data in recent literature regarding the management of radiation cystitis, at least by means of intravesical agents. The replenishment of the glycosaminoglycan layer of the bladder mucosa and the administration of botulinum toxin show promise, but need further investigation.
- 1 December 2015
- Published by Wolters Kluwer Health in Current Urology
- Vol. 8 (4) , 169-174
Intravesical Therapies for Radiation Cystitis
Objective: The purpose of this study was to summarize developments during the last decade in intravesical treatments for radiation cystitis. Radiation used to treat pelvic malignancies inadvertently damages the urinary bladder leading to acute as well as chronic symptoms. Late sequelae may take years to develop and include storage symptoms and hematuria, which may be life-threatening in severe cases. Conservative measures, surgical interventions, and systematically or intravesically administered agents represent treatment choices. Methods: MEDLINE and PubMed were searched to retrieve clinical data on the subject, published in peer-reviewed journals from 2002 onwards. Results: Historically referenced intravesical treatments such as aluminium salts and formalin, were not investigated in recent studies. The replenishment of the glycosaminoglycan layer of the bladder mucosa shows promise in reducing acute symptoms and possibly long-term bladder damage, but needs further investigation. Botulinum toxin also represents a new alternative treatment for radiation cystitis but its mechanism of action and efficacy should be evaluated in future trials. Conclusion: There is a paucity of data in recent literature regarding the management of radiation cystitis, at least by means of intravesical agents. The replenishment of the glycosaminoglycan layer of the bladder mucosa and the administration of botulinum toxin show promise, but need further investigation.
- 6 February 2015
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 15 (3) , 413-423
A review of cost–effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?
(2015). A review of cost–effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life? Expert Review of Pharmacoeconomics & Outcomes Research: Vol. 15, No. 3, pp. 413-423. doi: 10.1586/14737167.2015.1011132
- 6 February 2015
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 15 (3) , 413-423
A review of cost–effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?
(2015). A review of cost–effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life? Expert Review of Pharmacoeconomics & Outcomes Research: Vol. 15, No. 3, pp. 413-423. doi: 10.1586/14737167.2015.1011132
- 6 September 2014
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 68 (9) , 1165-1173
Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?
Overactive bladder and urgency incontinence are common and distressing conditions in older people, for which the first-line pharmacological treatment is a bladder antimuscarinic agent. Of these, oxybutynin is often recommended in guidelines, but is associated with a higher incidence of adverse drug effects, and in particular has been suggested to have deleterious cognitive effects. Despite this, guidelines often suggest oxybutynin as first-line treatment, and insurance based healthcare systems often require oxybutynin to be used as a first-line therapy and fail before reimbursement for the cost of newer anticholinergics is authorised. We reviewed the literature of bladder antimuscarinics in older adults, using the headings overactive bladder, urinary frequency, urgency, urge, oxybutynin, antimuscarinic, older, older people, and frail. In general, oxybutynin had a similar efficacy to other anticholinergic drugs, but a higher incidence of adverse drug events, in particular significant yet unnoticed cognitive impairment. We conclude that oxybutynin should not be used in frail older people.
- 6 September 2014
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 68 (9) , 1165-1173
Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?
Overactive bladder and urgency incontinence are common and distressing conditions in older people, for which the first-line pharmacological treatment is a bladder antimuscarinic agent. Of these, oxybutynin is often recommended in guidelines, but is associated with a higher incidence of adverse drug effects, and in particular has been suggested to have deleterious cognitive effects. Despite this, guidelines often suggest oxybutynin as first-line treatment, and insurance based healthcare systems often require oxybutynin to be used as a first-line therapy and fail before reimbursement for the cost of newer anticholinergics is authorised. We reviewed the literature of bladder antimuscarinics in older adults, using the headings overactive bladder, urinary frequency, urgency, urge, oxybutynin, antimuscarinic, older, older people, and frail. In general, oxybutynin had a similar efficacy to other anticholinergic drugs, but a higher incidence of adverse drug events, in particular significant yet unnoticed cognitive impairment. We conclude that oxybutynin should not be used in frail older people.